Aligos Therapeutics, Inc. Common Stock
Symbol: ALGS (NASDAQ)
10.89
▲ (1.63%) 0.175
Company Description:
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Key Stats
- Today's Open: $10.82
- Today's High: $10.955
- Today's Low: $10.2
- Today's Volume: 41.53K
- Yesterday Close: $10.71
- Yesterday High: $11.6499
- Yesterday Low: $10.7
- Yesterday Volume: 84.11K
- Last Min Volume: 2
- Last Min High: $10.885
- Last Min Low: $10.885
- Last Min VWAP: $10.885
Company Profile
- Name: Aligos Therapeutics, Inc. Common Stock
- Website: https://www.aligos.com
- Listed Date: 2020-10-16
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001799448
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $74.45M
- Round Lot: 100
- Outstanding Shares: 6.95M
- Asset Type: CS
RECENT FILINGS FOR ALGS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-06 | S-8 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-06 | 10-Q | View |
Latest News on ALGS